⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 1, 2022Clinical Cancer ResearchOpen Access

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC

View Full Paper

Ask AI

Bookmark

Share

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

A 2022 study studied this question.

synapsesocial.com/papers/6a7e5f217f55e1ae3983e96f https://doi.org/10.1158/1078-0432.ccr-21-3844

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

1FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond2017 · 297 citations
2Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)2019 · 355 citations
3Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer2019 · 1,125 citations